GlassScriptPhysician profile
William B Caudill
NPI 1922101492
$2,290.22
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $519 · 2021: $350 · 2022: $748 · 2023: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $403.27 | 2019-2022 | |
| Vifor Pharma, INC. | $334.37 | 2020-2023 | Veltassa, Korsuva |
| Amgen INC. | $315.12 | 2019-2023 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $222.10 | 2019-2021 | |
| Glaxosmithkline, LLC. | $171.62 | 2020-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $129.85 | 2021-2023 | Velphoro, Korsuva |
| Horizon Therapeutics Plc | $100.45 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.97 | 2022-2023 | |
| Travere Therapeutics, INC. | $61.60 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $59.32 | 2020-2022 | |
| Daiichi Sankyo INC. | $55.98 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $44.99 | 2022 | |
| Aurinia Pharma U.S., INC. | $42.92 | 2022 | |
| Opko Pharmaceuticals, LLC | $42.05 | 2019-2023 | Rayaldee |
| Shire North American Group INC | $38.08 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $34.86 | 2021 | |
| Genzyme Corporation | $32.89 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.42 | 2020 | |
| Amag Pharmaceuticals, INC. | $18.67 | 2019 | |
| Shield Therapeutics INC | $18.33 | 2022 | |
| Akebia Therapeutics INC | $16.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.04 | 2021 | |
| Xeris Pharmaceuticals, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Caudill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.